The FDA is urging patients who have received drugs from Fullerton Wellness to stop using them and contact their health care provider.

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

And FDA warned against the use of drugs compounded and distributed by California's Fullerton Wellness-- which include ...

Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and ...

The U.S. Food and Drug Administration on Friday warned patients and health care professionals not to use compounded drugs, ...

US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...

What started as treatments for type two diabetes, medications like Semaglutide and Tirzepatide have since been approved by ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...

Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...